REGENERON PHARMACEUTICALS, INC. (REGN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 6B 12B 18B FY08: 238.5M FY09: 379.3M FY10: 459.1M FY11: 445.8M FY12: 1.4B FY13: 2.1B FY14: 2.8B FY15: 4.1B FY16: 4.9B FY17: 5.9B FY18: 5.1B FY19: 6.6B FY20: 8.5B FY21: 16.1B FY22: 12.2B FY23: 13.1B FY24: 14.2B FY25: 14.3B FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-3.5B 0 3.5B 7B 10.5B FY08: -86.2M FY09: -74.1M FY10: -97.5M FY11: -205.2M FY12: 457.7M FY13: 743M FY14: 823.9M FY15: 1.3B FY16: 1.3B FY17: 2.1B FY18: 2.5B FY19: 2.2B FY20: 3.6B FY21: 8.9B FY22: 4.7B FY23: 4B FY24: 4B FY25: 3.6B FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-3B 0 3B 6B 9B FY08: -79.1M FY09: -67.8M FY10: -104.5M FY11: -221.8M FY12: 750.3M FY13: 413.7M FY14: 338.1M FY15: 636.1M FY16: 895.5M FY17: 1.2B FY18: 2.4B FY19: 2.1B FY20: 3.5B FY21: 8.1B FY22: 4.3B FY23: 4B FY24: 4.4B FY25: 4.5B FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 150M 300M 450M FY18: 237.5M FY19: 402.8M FY18 FY19

Operating Cash Flow Annual

-2.5B 0 2.5B 5B 7.5B FY08: -89.1M FY09: -69.9M FY10: 99.2M FY11: -141.7M FY12: -74.6M FY13: 588.6M FY14: 752.4M FY15: 1.3B FY16: 1.5B FY17: 1.3B FY18: 2.2B FY19: 2.4B FY20: 2.6B FY21: 7.1B FY22: 5B FY23: 4.6B FY24: 4.4B FY25: 5B FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-2.5B 0 2.5B 5B 7.5B FY08: -123.9M FY09: -167.3M FY10: -467K FY11: -198.9M FY12: -124M FY13: 432.3M FY14: 419.4M FY15: 652.8M FY16: 974M FY17: 1B FY18: 1.8B FY19: 2B FY20: 2B FY21: 6.5B FY22: 4.4B FY23: 3.9B FY24: 3.7B FY25: 4.1B FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 40M 80M 120M FY10: 82.9M FY11: 90.6M FY12: 115.4M FY13: 111.3M FY14: 113.4M FY15: 115.2M FY16: 116.3M FY17: 115.9M FY18: 114.8M FY19: 114.6M FY20: 115.1M FY21: 112.2M FY22: 113.5M FY23: 113.7M FY24: 115.1M FY25: 108.6M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-25.00 0.00 25.00 50.00 75.00 Q4 '10: -1.27 Q1 '11: -1.38 Q2 '11: -1.76 Q3 '11: -2.03 Q4 '11: -2.44 Q1 '12: -1.84 Q2 '12: -0.45 Q3 '12: 1.95 Q4 '12: 6.61 Q1 '13: 7.40 Q2 '13: 7.49 Q3 '13: 7.02 Q4 '13: 3.80 Q1 '14: 3.51 Q2 '14: 3.57 Q3 '14: 3.05 Q4 '14: 2.97 Q1 '15: 3.02 Q2 '15: 3.86 Q3 '15: 4.95 Q4 '15: 5.51 Q1 '16: 6.44 Q2 '16: 6.44 Q3 '16: 6.89 Q4 '16: 7.74 Q1 '17: 8.31 Q2 '17: 9.96 Q3 '17: 11.01 Q4 '17: 10.32 Q1 '18: 12.32 Q2 '18: 13.80 Q3 '18: 15.65 Q4 '18: 21.30 Q1 '19: 21.13 Q2 '19: 17.99 Q3 '19: 18.68 Q4 '19: 18.46 Q1 '20: 19.90 Q2 '20: 25.83 Q3 '20: 27.36 Q4 '20: 30.67 Q1 '21: 35.33 Q2 '21: 55.69 Q3 '21: 62.63 Q4 '21: 72.07 Q1 '22: 70.59 Q2 '22: 50.09 Q3 '22: 47.42 Q4 '22: 38.23 Q1 '23: 36.79 Q2 '23: 37.82 Q3 '23: 35.05 Q4 '23: 34.76 Q1 '24: 33.86 Q2 '24: 37.77 Q3 '24: 40.42 Q4 '24: 38.33 Q1 '25: 39.33 Q2 '25: 39.73 Q3 '25: 41.81 Q4 '25: 41.57 Q1 '26: 41.05 Q2 '26: 40.47 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.